Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone
Top Cited Papers
- 1 May 2016
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 59, 1-12
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of boneNature Genetics, 2013
- The efficacy of chemical adjuvants on giant-cell tumour of boneThe Journal of Bone and Joint Surgery. British volume, 2010
- Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of BoneBMC Cancer, 2010
- Primary Malignant Giant-Cell Tumor of Bone Has High Survival RateAnnals of Surgical Oncology, 2009
- Local Recurrence of Giant Cell Tumor of Bone After Intralesional Treatment with and without Adjuvant TherapyJournal of Bone and Joint Surgery, 2008
- Cement is recommended in intralesional surgery of giant cell tumors: A Scandinavian Sarcoma Group study of 294 patients followed for a median time of 5 yearsActa Orthopaedica, 2008
- Giant cell tumour of bone: morphological, biological and histogenetical aspectsInternational Orthopaedics, 2006
- RANK Expression as a Cell Surface Marker of Human Osteoclast Precursors in Peripheral Blood, Bone Marrow, and Giant Cell Tumors of BoneJournal of Bone and Mineral Research, 2006
- RANK (Receptor Activator of Nuclear Factor kappa B) and RANK Ligand Are Expressed in Giant Cell Tumors of BoneAmerican Journal of Clinical Pathology, 2002
- The nature of giant cell tumor of boneJournal of Cancer Research and Clinical Oncology, 2001